WASHINGTON, D.C. — Erica Schwartz is scheduled to appear before the Senate Health, Education, Labor and Pensions Committee for a confirmation hearing on July 15, 2026. If confirmed, she would become director of the Centers for Disease Control and Prevention (CDC) under Department of Health and Human Services Secretary Robert F. Kennedy Jr., filling a leadership role that has seen rapid turnover and political turbulence over the past year.

Schwartz was nominated for the CDC director position in mid-April 2026, following the withdrawal of Dr. Dave Weldon’s nomination just before his confirmation hearing due to insufficient Senate support. Prior to her nomination, Schwartz served as chief medical officer of the U.S. Coast Guard and as deputy surgeon general during the first Trump administration, from January 2019 to April 2021. She is a retired rear admiral in the U.S. Public Health Service Commissioned Corps and holds degrees in medicine, law, and public health.

Earlier in 2026, Schwartz voiced support for vaccines as tools to prevent illness and promote readiness in the military in a post on Instagram. Her Instagram page was removed after she was nominated for the CDC director role. This digital silence comes heightened scrutiny of public health leadership under Secretary Kennedy, whose recent changes to children’s vaccine policies have been blocked by a federal judge.

Supporters describe Schwartz as a stabilizing figure for an agency under strain. “People are very optimistic about her candidacy and are supportive of her potentially being in the role,” said Marcus Plescia, district health director for Fulton County. He added, “What we really need right now is a CDC director who can step in and be a spokesperson on some of the emerging issues we're facing.” Plescia emphasized continuity, stating, “We need somebody in that position who can get in and establish themselves and be there to stay.”

The CDC has faced internal disruption since early 2025. Susan Monarez received Senate confirmation as CDC director in summer 2025 but served for less than a month before being fired by Secretary Kennedy. Internal CDC emails released by Sen. Bernie Sanders cover the period from January through August 2025 and reveal deepening tensions between agency scientists and political leadership.

On Aug. 19, 2025, Matt Buckham, chief-of-staff to Secretary Kennedy, emailed Monarez stating, “I wanted to elevate the absolute need for political review of major policy decisions at CDC.” Buckham added, “Please err on the side of caution,” and signed the message with “Make America Great!”

Current CDC leadership has acknowledged the toll of this instability. Sean Slovenski, the agency’s deputy director and chief operating officer, told staff, “I've heard a lot … from people about what the morale is like here, how we've gotten to a point where it's not as happy as it used to be, the stress level's extremely high.” He noted the cumulative effect of leadership changes, saying, “If any organization went through one of the things you've had to endure in the last year and a half, it would be traumatic to that organization, institution, for years to come.” He added, “You've had multiple ones.”

Slovenski offered a message of clarity, if not reassurance. “I'm not promising that everyone will be happy,” he said. “What I'm promising is that everyone will be clear. Everyone will know what's coming and they'll know it was done in the most thoughtful manner.”

Critics of the current administration’s approach to public health remain skeptical. Georges Benjamin, head of the American Public Health Association, said, “The political agenda is still there.” He added, “The president said he was going to let the secretary go wild, and he did,” and noted, “He's now had to pull him back because it is creating political damage.”

The CDC director role carries national and global significance, overseeing responses to disease outbreaks, chronic illness prevention, and public health emergencies. The agency has lacked stable leadership since July 2025, when Monarez was abruptly dismissed after less than a month in office—a pattern that followed the withdrawal of Weldon’s nomination. With Kennedy’s vaccine policy changes already halted by judicial order, Schwartz’s confirmation could either restore scientific credibility to the agency or further entrench political oversight, depending on her approach and autonomy.

Schwartz’s public advocacy for military vaccine readiness and her extensive government service may position her as a consensus candidate. Yet her ability to operate independently under Kennedy—who has overseen controversial directives requiring political review of CDC decisions—will likely be a central focus of her July 15 hearing. The outcome will shape the CDC’s capacity to respond to emerging health threats ongoing institutional strain.